Offering to “empower more use cases” in healthcare delivery and clinical research, according to Chris Zant, chief digital officer for ConvergeHealth, Deloitte is introducing the MyPath platform in two versions, MyPath for Health and MyPath for Connected Care. ConvergeHealth was […]
Read MoreA pair of announcements involving TraceLink, a leading provider of software for compliance with the Drug Supply Chain Security Act (DSCSA) point to the future value of DSCSA’s original purpose: to more closely track pharmaceutical packages as they flow through […]
Read MoreAmong ~5.8 billion prescriptions filled each year, about 2 percent (or 116 million) are written for specialty therapies.[1] These medications can be highly complex and significantly more expensive than traditional pharmaceuticals – presenting patients with some of the most difficult […]
Read MoreOn the surface, the acquisition by Veeva seems to be a lot of money for what it’s getting—the purchase price works out to about $2.4 million per Crossix employee (there’s also $120 million in “long-term equity grants” involved). Veeva can […]
Read More
Qu4rtet, an IT solution for Level 4 compliance with the Drug Supply Chain Security Act (DSCSA), has a first publicly-announced commercial user: Sovereign Pharmaceuticals, a Fort Worth, TX, developer of generic products and 505(b)2 submissions. Since literally hundreds of manufacturers, […]
Read More
According to a white paper just published by a blockchain development company, LedgerDomain, preliminary testing of a blockchain-based network, called KitChain, met or exceeded the expectations of the pharma companies and service providers who joined in the effort. The goal […]
Read MoreAs is becoming better understood daily, individualized treatments like cellular and genetic therapies (CGTs) require close collaboration across healthcare: from clinics and hospitals, to pharma manufacturers and back, with logistics providers, blood centers and other participants along the way, the […]
Read MoreWhen Integrichain acquired DaVIZta last spring, it also picked up an initiative that that organization had started, the Revenue Analytics Collaborative, for life sciences execs involved in such issues as gross-to-net (GTN) analysis and revenue management. Now, IntegriChain is restarting […]
Read MoreIn 2018, the US FDA approved 63 novel drugs and biologics—and a staggering 44 of the approved products are considered specialty. The prevalence of specialty products launching and progressing through the development pipeline is giving rise to a nearly equal […]
Read MoreAs of mid-year, the National Council for Prescription Drug Plans (NCPDP), a standards-setting organization for pharmacy-related practices, is halfway to its goal of attaching a unique code to nearly all US patient identities, the “universal patient identifier” (UPI). (As of […]
Read More